Last reviewed · How we verify
IBI305
IBI305 is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses.
IBI305 is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Gastric cancer, Esophageal cancer.
At a glance
| Generic name | IBI305 |
|---|---|
| Also known as | Bevacizumab Biosimilar, Bevacizumab, anti-VEGF monoclonal antibody |
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
IBI305 is a fully human monoclonal antibody that targets programmed death ligand 1 (PD-L1). By binding to PD-L1, it prevents the engagement of PD-1 and B7.1 receptors on T cells, reversing tumor-mediated immune suppression and allowing cytotoxic T lymphocytes to recognize and eliminate cancer cells. This mechanism is similar to other checkpoint inhibitors in the PD-L1/PD-1 pathway.
Approved indications
- Non-small cell lung cancer
- Gastric cancer
- Esophageal cancer
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI305 CI brief — competitive landscape report
- IBI305 updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI